Aptevo Therapeutics
APVO
5 hedge funds and large institutions have $22.8K invested in Aptevo Therapeutics in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 6 closing their positions.
1.98% less ownership
Funds ownership: 3.32% → 1.34% (-2%)
29% less funds holding
Funds holding: 7 → 5 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
89% less capital invested
Capital invested by funds: $209K → $22.8K (-$186K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$36.7K |
| 2 |
CS
Clear Street
New York
|
+$10.1K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$7.59K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.59K |
| 5 |
SS
SBI Securities
Tokyo,
Japan
|
+$2.53K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$93K |
| 2 |
HF
HRT Financial
New York
|
-$53K |
| 3 |
JP Morgan Chase
New York
|
-$19.5K |
| 4 |
DP
Diadema Partners
Morristown,
New Jersey
|
-$17.5K |
| 5 |
Morgan Stanley
New York
|
-$13.9K |
APVO Hedge Fund Activity: Q1 2025 in Review
5 of the 7,473 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q1 2025, worth a combined $22.8K — down 89% from $209K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of APVO and 4 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $36.7K. The largest seller was Virtu Financial, exiting entirely with an estimated $93K sold.
- 5 institutional investors held Aptevo Therapeutics (APVO) as of Q1 2025, down from 7 in Q4 2024.
- Funds reported $22.8K of Aptevo Therapeutics stock for Q1 2025, down 89% quarter-over-quarter.
- 4 funds opened new Aptevo Therapeutics positions in Q1 2025 and 6 closed out, a net change of -2 holders.
- The largest Aptevo Therapeutics buyer in Q1 2025 was Geode Capital Management, an estimated $36.7K added.
- The largest Aptevo Therapeutics seller in Q1 2025 was Virtu Financial, an estimated $93K sold.
Based on aggregated 13F filings for Q1 2025.